EUCTR2007-002598-30-IT进行中（未招募）不适用
Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH: a double-blind placebo-controlled efficacy study - ND
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Benign Prostatic Hyperplasia, based on medical history; 2. Voiding symptoms: IPSS ≥ 13; 3. 50 years or older (at time of randomization); 4. Complete Week 52 visit to be eligible to the open-label phase. 5. Uroflow (max) 5 - 15 mL/sec. For repeat bone mineral density assessment at Week 52 6. Normal BMD at baseline (T-score between -1 SD to +1 SD, based upon young normal males).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Safety concerns: 1. Urgent need for prostate surgery; 2. Serum PSA ≥ 10 ng/ml; a patient with serum PSA > 4 ng/ml (but < 10 ng/ml) is only eligible if prostate cancer has been excluded to the satisfaction of the investigator (e.g., by prostate biopsy). ; 3. History of allergic reactivity to peptide hormones; 4. Eczema (atopic dermatitis) treated during the last 6 months; 5. Clinical significant increase of bleeding time (e.g., caused by idiopathic bleeding disorders and chronic anticoagulation therapy) and any other clinical condition that may interfere with the administration of study medication by intramuscular injection (e.g., local infection, paresis, and paralysis at the site of injection); 6. Major organ dysfunction, e.g., insulin-dependent diabetes, recent myocardial infarction (within 6 months of enrolment), history of unstable angina or newly diagnosed angina pectoris, current congestive heart failure, uncontrolled hypertension, current serious arrhythmia, use of concomitant Class 1A or Class III antiarrhythmic medications, personal or family history of long QT syndrome, clinically relevant ECG abnormalities (including QT/QTc interval > 450 ms) or clinically relevant chronic or acute infections; Lack of suitability for the trial: 7. Prior surgical treatment of the prostate or bladder; 8. Current or recent treatment with sexual hormone drugs or 5α reductase inhibitors or botulinum toxin type a (Botox) within the last 6 months prior to randomization at Week 0 or with α blockers or saw palmetto within the last 6 weeks prior to randomization at Week 0 (see list of drugs in section 6.3.1); 9. Newly started treatment with tricyclic antidepressants, cholestyramine, disopyramide, ketoconazole, and anticholinergics drugs (see list of drugs in section 6.3.1). An ongoing treatment at a stable dosage during the entire study is acceptable; 10. Urologic disorders including neurogenic bladder dysfunction due to diabetes mellitus or documented neurologic disorder, urethral stricture disease or history of pelvic radiation therapy; 11. History of acute obstructive, infectious, or neurological disorders of the genitourinary tract within the last 3 months; 12. Residual urine volume of > 350 mL; 13. Neurological, psychiatric disease, drug or alcohol abuse which could interfere with the patient?s proper compliance; Administrative reasons: 14. Lack of ability or willingness to give written informed consent; 15. Anticipated non-availability for study visits/procedures. For a patient considered for baseline bone mineral density assessment at Screening: 16. History of osteoporosis with or without fracture, osteopenia, alcoholism, hyperparathyroidism, hypoparathyroidism or hyperthyroidism. 17. Currently receiving or have received in the previous 12 months any medication that affects bone mineral density [including any treatment for osteoporosis, anticonvulsant therapy, chronic heparin treatment (> 3 months), systemic corticosteroids, methotrexate]. 18. Presence of a condition that would interfere with an accurate DEXA scan interpretation (i.e. history of lumbar laminectomy, bilateral hip prosthesis, severe lumbar scoliosis).
研究者
相似试验
进行中（未招募）
1 期
Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH: a double-blind placebo-controlled efficacy studyEUCTR2007-002598-30-FRAeterna Zentaris GmbH400
进行中（未招募）
不适用
Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH: an open-labeled safety and efficacy assessment studyBenign Prostatic Hyperplasia (BPH)MedDRA version: 9.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaEUCTR2007-004865-17-BGAeterna Zentaris GmbH500
进行中（未招募）
1 期
Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH: a double-blind placebo-controlled efficacy studyBenign Prostatic Hyperplasia (PBH)MedDRA version: 9.1 Level: LLT Classification code 10004446 Term: Benign prostatic hyperplasiaEUCTR2007-002598-30-GBAeterna Zentaris GmbH400
进行中（未招募）
不适用
Cetrorelix pamoate in patients with symptomatic BPH: a double-blind placebo-controlled efficacy studyBenign Prostatic Hyperplasia (PBH)MedDRA version: 9.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaEUCTR2007-002598-30-NLAeterna Zentaris GmbH400
进行中（未招募）
不适用
Cetrorelix pamoate in patients with symptomatic BPH: a double-blind placebo-controlled efficacy studyBenign Prostatic Hyperplasia (PBH)MedDRA version: 9.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaEUCTR2007-002598-30-CZAeterna Zentaris GmbH400